Johnson & Johnson will expand its cancer treatment portfolio with the $3.05 billion acquisition of Halda Therapeutics, announced Monday. The deal underscores the pharmaceutical giant’s continued investment in oncology-a segment facing high demand as cancer remains a leading cause of mortality globally-and represents J&J’s third significant acquisition in the healthcare space as the beginning of 2024 [[2]]. halda’s innovative RiPTAC technology offers a perhaps targeted approach to treating solid tumors and prostate cancer, even after resistance to standard therapies has developed.
Johnson & Johnson (J&J) announced Monday, May 13, it will acquire Halda Therapeutics, a pharmaceutical company specializing in cancer therapies, for $3.05 billion. The acquisition expands J&J’s portfolio in treatments for solid tumors and prostate cancer, areas of significant unmet medical need.
The deal is expected to be finalized within the coming months. Investing in new cancer treatments is crucial as the disease remains a leading cause of death worldwide.
Halda’s lead drug candidate, HLD-0915, is currently in early-to-mid-stage development as a potential treatment for prostate cancer. The company also has several other experimental therapies in the early stages of development targeting breast cancer, lung cancer, and other tumor types.
“Their innovative technology is designed to work even when cancers stop responding to standard treatments, utilizing a novel mechanism that allows for the selective elimination of cancer cells,” said John Reed, Executive Vice President of Pharmaceutical Research and Development at Johnson & Johnson, according to Reuters.
Halda’s RiPTAC technology works by linking a tumor marker to a protein essential for cell survival, selectively disabling that protein within cancer cells and leading to their destruction, while leaving healthy cells unharmed. This targeted approach aims to minimize side effects often associated with traditional cancer treatments.
The acquisition aligns with J&J’s strategy to grow its faster-growing health segments through new product launches, offsetting the impact of expiring patents. Maintaining a robust pipeline of innovative therapies is essential for pharmaceutical companies to remain competitive.
This is J&J’s second major acquisition this year, following the January announcement of its $14.6 billion acquisition of Intra-Cellular Therapies, a neurological pharmaceutical company.
J&J has also made several other acquisitions in recent years to strengthen its pharmaceutical and medical device divisions, including the $13.1 billion acquisition of Shockwave Medical in 2024. These strategic investments demonstrate J&J’s commitment to expanding its presence in key healthcare markets.
